Effect of Ulinastatin combined with HFNC in the Treatment of Severe Pneumonia and ARDS

JI Chengyi; ZHENG Xiayun; CHEN Qiuyan

doi:10.14033/j.cnki.cfmr.2024.30.009

Abstract：Objective:To explore the effects of Ulinastatin combined with high flow nasal cannula (HFNC) on patients with severe pneumonia and acute respiratory distress syndrome (ARDS). Method:98 patients with severe pneumonia and ARDS diagnosed in Xiamen Third Hospital from January 2022 to October 2023 were selected as the study objects,and were divided into group A (n=51 cases,Ulinastatin combined with HFNC treatment) and group B (n=47,NFNC treatment) according to the different treatment options. Both groups were treated continuously for 7 days. The oxygenation status (PaO2,PaCO2,PaO2/FiO2,pH value),hemodynamics[heart rate (HR),mean arterial pressure (MAP)]and inflammatory factorsC-reactive protein (CRP),interleukin-6 (IL-6),tumor necrosis factor-α(TNF-α) were compared between the two groups. The occurrence of adverse reactions in the two groups was observed. Result:After treatment,PaO2,PaO2/FiO2 and pH in both groups were higher than before treatment,and group A was higher than group B,PaCO2 in both groups was lower than before treatment,and group A was lower than group B,the difference was statistically significant (P<0.05). After treatment,MAP was higher and HR was lower in both groups than before treatment,the difference was statistically significant (P<0.05). After treatment,the levels of inflammatory factors in both groups were lower than before treatment,and group A was lower than group B,with statistical significance (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion:Ulinastatin combined with HFNC can effectively further reduce the level of inflammatory factors,improve the oxygenation status of patients,stabilize the hemodynamics of patients,improve clinical efficacy,and have safety.